News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Hungary's opposition Tisza party won a two-thirds parliamentary majority, ending Viktor Orbán's 16-year rule.
  • U.S.-Iran negotiations in Islamabad ended without agreement and the U.S. says it will begin a Strait of Hormuz blockade.
  • The U.S. dollar strengthened in early Asia trade after the talks stalled, weighing on the euro and yen.
  • Oil prices rose on Strait of Hormuz tensions, reviving inflation concerns for markets and policymakers.
  • Moscow equities slid with MOEX hitting a one-month low amid mixed commodity and FX moves.
  • Djibouti's President Ismael Omar Guelleh secured a sixth term with about 97.8% of the vote.

Latest Articles

Acadia CFO Sells $159k in Stock as RSUs Vest; Company Faces EU Setback

Acadia CFO Sells $159k in Stock as RSUs Vest; Company Faces EU Setback

Acadia Pharmaceuticals Chief Financial Officer Mark C. Schneyer sold 7,385 shares between March 25 and March 26, 2026, to cover withholding taxes tied to vested restricted stock units. The transactions generated approximately $159,135 in proceeds. Schneyer also received 14,316 shares on March 24 and 25 upon RSU vesting. The company recently reporte…

Acadia EVP Executes Option Exercise, Sells Shares Worth About $73,749

Acadia EVP Executes Option Exercise, Sells Shares Worth About $73,749

Elizabeth H.Z. Thompson, Executive Vice President and Head of Research & Development at Acadia Pharmaceuticals, disclosed an option exercise and subsequent sale that generated roughly $73,749. The trades were reported on a Form 4 and follow corporate developments including a regulatory negative opinion on trofinetide in Europe, a brokerage upgrade,…

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences, a clinical-stage pharmaceutical company, has entered into definitive agreements for a private placement under Nasdaq rules to raise approximately $11 million by issuing 3.19 million common shares or pre-funded warrants along with warrants exercisable for up to 6.38 million shares. The financing proceeds will be used for working …

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Zenas BioPharma announced the pricing of concurrent public offerings including $200 million aggregate principal amount of 2.50% convertible senior notes due 2032 and 5 million shares of common stock priced at $20.00 per share, aiming to raise approximately $287.5 million net proceeds. The funds will support the planned U.S. commercial launch of obe…

Moomoo and the New York Mets Enter Second Year of Strategic Partnership to Continue Enhancing the Fan Experience

Moomoo and the New York Mets Enter Second Year of Strategic Partnership to Continue Enhancing the Fan Experience

Moomoo, a global investment and trading platform and a subsidiary of the Nasdaq-listed FHL Holdings, is entering the second year of its partnership with the New York Mets. The collaboration aims to enhance the fan experience at Citi Field through suite experiences, interactive events, and community engagement throughout the 2026 MLB season. The par…

Cambridge Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing March 30, 2026

Cambridge Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing March 30, 2026

Cambridge Acquisition Corp., a U.S.-based SPAC listed on Nasdaq, announced that starting March 30, 2026, investors will be able to separately trade its Class A ordinary shares and warrants, which were previously bundled as units. The shares and warrants will trade under the tickers 'CAQ' and 'CAQUW' respectively, while unsplit units will continue u…

Terra Property Trust, Inc. Announces Final Results of Registered Exchange Offers and Consent Solicitation

Terra Property Trust, Inc. Announces Final Results of Registered Exchange Offers and Consent Solicitation

Terra Property Trust, Inc. disclosed the results of its exchange offers to swap existing unsecured senior notes due in 2026 for new secured senior notes due in 2029. While substantial tendering of existing notes occurred, the company did not receive sufficient consents to amend the indenture governing its 6.00% senior notes, so the proposed amendme…

Hudbay Provides Annual Reserve and Resource Update with Mine Life Extensions and Improved Three-Year Production Outlook

Hudbay Provides Annual Reserve and Resource Update with Mine Life Extensions and Improved Three-Year Production Outlook

Hudbay Minerals Inc. announced its annual mineral reserve and resource update, highlighting mine life extensions across its operations and a significantly improved three-year production forecast. The company affirmed its 2026 production guidance and issued new guidance for 2027 and 2028, projecting a 24%-28% increase in consolidated copper producti…

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

PMGC Holdings Inc.'s subsidiary NorthStrive Biosciences announced a third amendment to its license agreement with Korean biotech MOA Life Plus updating timelines and development milestones for dual myostatin inhibitor assets EL-32 and EL-22, focusing on muscle preservation during weight loss treatment. The amendment reflects aligned R&D and regulat…

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) with the FDA seeking approval for IGALMI in an at-home setting to treat acute agitation associated with bipolar disorders and schizophrenia. The timeline suggests potential approval as early as year-end 2026. The company is advancing commercial launch plans based on a rec…

Cue Biopharma Announces CEO Transition

Cue Biopharma Announces CEO Transition

Cue Biopharma announced a CEO transition with Lucinda Warren stepping in as interim president and CEO following Usman Azam's departure. Warren brings over 30 years of pharmaceutical and biotech experience and has been instrumental in securing key deals for the company. The firm plans to advance its lead autoimmune therapy, CUE-401, into clinical tr…